Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Bull Horn Holdings (BHSEU)
New Beginnings Acquisition (NBA.U)
CONX (CONXU)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Cerberus Telecom Acquisition (CTACU)
Upcoming IPO
OTR Acquisition (OTRAU)
Natural Order Acquisition (NOACU)
Priced IPO
Allegro MicroSystems, Inc. (ALGM)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Absolute Software (ABST)
EQT Corporation (EQT)
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
More companies

Immunome Inc. (IMNM)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a biopharmaceutical company utilizing their proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Their proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Their platform is differentiated from those of other biotechnology companies because of their unbiased, broad, deep and efficient approach to identifying novel antibody-target pairs that may be useful in treating cancer and infectious diseases. To date, they have processed more than 150 cancer patient memory B cell samples and have generated and screened more than 250,000 hybridomas, or forms of B cell clones, produced by fusion with an immortal partner cell line. The resulting immortalized hybrid cells produce a single antibody for extended periods of time, and they have successfully identified approximately 1,200 individual antibodies, which they refer to as hits, that appear to bind either a cancer cell or a tumor extract with high-affinity and specificity. One of these unique targets is interleukin-38 a small protein, secreted by various cells of the body, which appears to function as a novel immune checkpoint inhibitor, and is the current focus of their lead discovery program, IMM-ONC-01. Upon successful completion of their preclinical evaluation, they expect to file an investigational new drug, or IND, application with the FDA in connection with this program in the second half of 2021.
Industry
Pharmaceuticals
CEO CFO
Purnanand D. Sarma Richard F. Fitzgerald
Employees Founded
2006

Contacts

Address: 665 Stockton Drive, Suite 300 Exton, PA 19341

Telephone: (610) 321-3700

Web page: http://www.immunome.com

IPO information

Expected Date 10/2/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) -
Revenues (MM) $
Net Income (Loss) (MM) $

Voting

What do you think will happen with the IMNM share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 2.5
Shares Revised (MM) 3.25
Expected offer amount (MM) $30
Realized offer amount(MM) $39
Underwriters
Ladenburg Thalmann/ Chardan
CO-Managers
-

Sector: Healthcare

Tweets about $IMNM

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats